“Our data suggest SGLT2 inhibition as a safe strategy to prevent kidney stone recurrence in patients with kidney stones ,” Dr Fuster’s team concluded. Other study findings indicate the empagliflozin ...

GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...

“Our data suggest SGLT2 inhibition as a safe strategy to prevent kidney stone recurrence in patients with kidney stones,” Dr Fuster’s team concluded. Other study findings indicate the ...

The use of SGLT2 vs DPP4 inhibitors was linked to reduced cardiovascular and renal risks among patients with comorbid SLE and T2D.

The effects of SGLT2 inhibitors on the kidney to prevent progression of chronic kidney disease, congestive heart failure, ...

Starting SGLT2 inhibitors led to a lower risk of eGFR decline or incident kidney failure. SGLT2 inhibitors were also linked to reduced amputation and AKI risks. Use of SGLT2 inhibitors was ...

Teams of researchers are investigating empagliflozin and dapagliflozin in patients with autosomal dominant polycystic kidney disease (AD PKD).

RADNOR, Pa. - Mineralys Therapeutics , Inc. (NASDAQ:MLYS), a biopharmaceutical company specializing in the development of treatments for cardiovascular and kidney diseases, has announced the ...

"These findings reinforce the use of dapagliflozin, 10 mg, or other SGLT2 inhibitors when the therapeutic goal is to reduce ...

A higher risk of HF hospitalization was seen with dapagliflozin over empagliflozin, but one researcher urges caution.

New research shows diabetes medication SGLT-2 inhibitors lower dementia risk by up to 35%, offering hope for millions ...

and chronic kidney injury. The combination therapy of [SGLT2 inhibitor] and GLP-1RA was associated with reduced risks of cardiorenal adverse events when compared with monotherapy of either agents ...